miRNA与非小细胞肺癌顺铂耐药的研究进展

详细信息    查看全文 | 推荐本文 |

英文篇名：Research Progress of MiRNA and Cisplatin Resistance of Non-small Cell Lung Cancer 作者：方亚妮 英文作者：FANG Ya-ni;Department of medical technology, Shaanxi University of Chinese Medicine; 关键词：非小细胞肺癌 ; 顺铂耐药 ; miRNA 英文关键词：Non-small cell lung cancer;;Cisplatin resistance;;MicroRNA 中文刊名：WMIA 英文刊名：World Latest Medicine Information 机构：陕西中医药大学医学技术学院; 出版日期：2019-06-21 出版单位：世界最新医学信息文摘 年：2019 期：v.19 语种：中文; 页：WMIA201950059 页数：2 CN：50 ISSN：11-9234/R 分类号：129-130

摘要

以顺铂为基础的化疗是治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的主要临床手段,而患者对其产生的耐药现象严重影响了顺铂的治疗效果。近年来的研究表明,miRNA在非小细胞肺癌的发生和发展中扮演着关键的角色,并参与了调节顺铂的药物敏感性。本文就将miRNA与非小细胞肺癌的相关研究做一综述,希望可以为NSCLC的临床研究提供新的方向。
        Cisplatin-based chemotherapy is the main clinical method for the treatment of advanced NSCLC patients, however,acquired resistance to cisplatin-based chemotherapy had been one of the major obstacles in the clinical treatment of NSCLC. Recently,it has been reported that miRNAs play critical roles in the development and progression of cancer, and they were also involved in regulating the drug sensitivity of cisplatin. In this paper, the relevant studies on miRNAs and non-small cell lung cancer were reviewed,hoping to provide a new direction for clinical research on NSCLC.

引文

[1]Chen W.,Zheng R.,Baade P.D.,et al.Cancer statistics in China,2015[J].CACancer J Clin,2016,66(2):115-132.
    [2]Ettinger D.S.,Wood D.E.,Akerley W.,et al.NCCN Guidelines Insights Non-Small Cell Lung Cancer,Version 4.2016[J].J Natl Compr Canc Netw,2016,14(3):255-264.
    [3]Zhou F.,Jiang T.,Ma W.,et al.The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer:Asystematic review with meta-analysis[J].Lung Cancer,2015,89(2):203-211.
    [4]Barger JF,Nana-Sinkam SP.MicroRNA as tools and therapeutics in lung cancer[J].Respiratory medicine,2015,109(7):803-812.
    [5]翁克贵,王颖,蒋勇.miRNA-21靶向调控Wnt/β-catenin对非小细胞肺癌细胞增殖与侵袭的影响[J].中国组织化学与细胞化学杂志,2018(06):514-520.
    [6]高晓会,张亚利,陈小兵.miR-21靶向Atg5对非小细胞肺癌A549细胞自噬调控促进细胞增殖、迁移和侵袭的实验研究[J].临床肿瘤学杂志,2019,24(02):97-101.
    [7]张宁,卢创新,务森,等.miR-138-5p在非小细胞肺癌中的表达及临床意义[J].临床肿瘤学杂志,2019,24(02):149-152.
    [8]赵天增,杨金华,刘向前,等.miR-145通过靶向AP4对非小细胞肺癌A549细胞迁移侵袭的影响[J].肿瘤防治研究,2019,46(02):110-114.
    [9]刘明明,刘永侠,付子毅.miR-34a逆转非小细胞肺癌A549/DDP细胞对顺铂的耐药性及其机制[J].中国老年学杂志,2016,36(01):52-54.
    [10]Liu MX,Zhou KC,Cao Y.MCRS1 overexpression,which is specifically inhibited by miR-129*,promotes the epithelial-mesenchymal transition and metastasis in non-small cell lung cancer[J].Molecular cancer,2014,13:245.
    [11]Li J,Wang Y,Song Y,et al.miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells[J]Molecular cancer,2014,13:193.
    [12]Yang Y,Zhang P,Zhao Y,et al.Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer[J].Cancer biology&therapy,2016,17(5):515-525.
    [13]Qiu T,Zhou L,Wang T,et al.miR-503 regulates the resistance of non-smal cell lung cancer cells to cisplatin by targeting Bcl-2[J].International journal of molecular medicine,2013,32(3):593-598.
    [14]Zhu W,Zhu D,Lu S,et al.miR-497 modulates multidrug resistance of human cancer cell lines by targeting BCL2[J].Medical oncology,2012,29(1):384-391.
    [15]Tung MC,Lin PL,Cheng YW,et al.Reduction of microRNA-184 by E6oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2[J]Oncotarget,2016,7(22):32362-32374.
    [16]刘文秀,曹博,王兴宁.循环miR-29a和miR-150与非小细胞肺癌胸部放射治疗剂量的相关性[J].现代肿瘤医学,2018,26(05):708-712.
    [17]Bemis LT,Weiss GJ,Nakajima E,et al.EGFR regulation by microRNA in lung cancer:correlation with clinical response and survival to gefitinib and EGFR expression in cell lines[J].Ann Oncol,2008,19(6):1053-1059.
    [18]林剑勇,肖树荣,邓益斌.MiRNA在肺癌诊断与治疗中的应用进展[J]右江医学,2016,44(05):580-582.